Technical Analysis for CYTR - CytRx Corporation

Grade Last Price % Change Price Change
grade D 0.5599 1.10% 0.01
CYTR closed up 1.1 percent on Friday, May 24, 2019, on 28 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Up
See historical CYTR trend table...

Date Alert Name Type % Chg
Calm After Storm Range Contraction 0.00%
Narrow Range Bar Range Contraction 0.00%
NR7 Range Contraction 0.00%
Inside Day Range Contraction 0.00%
Spinning Top Other 1.10%
Calm After Storm Range Contraction 1.10%
Down 3 Days in a Row Weakness 1.10%
Calm After Storm Range Contraction -0.90%
1,2,3 Pullback Bullish Bullish Swing Setup -2.44%
Calm After Storm Range Contraction -2.44%

Older signals for CYTR ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
CytRx Corporation is a biopharmaceutical research and development company specializing in oncology. Its oncology pipeline includes two programs, aldoxorubicin and tamibarotene, which are in clinical development for cancer indications. The aldoxorubicin is in pivotal Phase 3 preparation ongoing stage of development for patients with soft tissue sarcomas whose tumors have progressed following treatment with chemotherapy. The company also has initiated an international Phase 2b clinical trial as a treatment for soft tissue sarcomas; completed its Phase 1b/2 clinical trial primarily in the same indication; and initiated a Phase 1b pharmacokinetics clinical trial in patients with metastatic solid tumors and a Phase 1b study of aldoxorubicin in combination with doxorubicin in patients with advanced solid tumors. Tamibarotene is being tested in a double-blind, placebo-controlled, international Phase 2b clinical trial in patients with non-small-cell lung cancer. In addition, the company is evaluating a third drug candidate, bafetinib, in the ENABLE Phase 2 clinical trial in high-risk B-cell chronic lymphocytic leukemia. CytRx Corporation was founded in 1985 and is headquartered in Los Angeles, California.
Medicine Cancer Drugs Oncology Chemotherapy Monoclonal Antibodies Cancer Treatments Non Small Cell Lung Cancer Tumors Pharmacokinetics Advanced Solid Tumors Metastatic Solid Tumors Anthracyclines Evofosfamide
Is CYTR a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 3 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 1.37
52 Week Low 0.33
Average Volume 157,889
200-Day Moving Average 0.7208
50-Day Moving Average 0.6061
20-Day Moving Average 0.54
10-Day Moving Average 0.5519
Average True Range 0.0432
ADX 25.72
+DI 17.6412
-DI 15.405
Chandelier Exit (Long, 3 ATRs ) 0.4904
Chandelier Exit (Short, 3 ATRs ) 0.5946
Upper Bollinger Band 0.5848
Lower Bollinger Band 0.4952
Percent B (%b) 0.72
BandWidth 16.592593
MACD Line -0.0072
MACD Signal Line -0.0154
MACD Histogram 0.0083
Fundamentals Value
Market Cap 92.79 Million
Num Shares 166 Million
EPS -0.41
Price-to-Earnings (P/E) Ratio -1.37
Price-to-Sales 593.24
Price-to-Book 2.86
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.59
Resistance 3 (R3) 0.59 0.57 0.58
Resistance 2 (R2) 0.57 0.57 0.57 0.58
Resistance 1 (R1) 0.57 0.56 0.57 0.57 0.58
Pivot Point 0.55 0.55 0.56 0.56 0.55
Support 1 (S1) 0.55 0.55 0.55 0.55 0.54
Support 2 (S2) 0.53 0.54 0.54 0.54
Support 3 (S3) 0.53 0.53 0.54
Support 4 (S4) 0.53